VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC® Oncology Pipeline

VERAXA Biotech (NASDAQ: VRXA) has appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer. In this role, Dr. Erkel will be responsible for advancing the company’s proprietary BiTAC® technology and broader oncology pipeline toward clinical development. The lead BiTAC-TCE program employs a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, and preclinical data presented at the AACR Annual Meeting demonstrated selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug conjugates and other engineered antibody therapies, positioning the company to pursue multiple approaches to next-generation cancer treatment.

To view the full article, visit https://ibn.fm/dSC1p. VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit www.VERAXA.com.

BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.